The part number 20G11GB2P2JA0NNNNN appears to be related to a clinical research study focused on type 2 diabetes and obesity. The study is investigating the efficacy and safety of an oral, small-molecule glucagon-like peptide-1 receptor agonist called danuglipron for managing blood glucose and weight in patients with type 2 diabetes. The study is a randomized, placebo-controlled, Phase 2 trial that aims to assess the tolerability, safety, and pharmacodynamics of danuglipron.
The study is designed to compare the effects of danuglipron with those of insulin therapy in patients with type 2 diabetes and excess weight who are at risk for heart disease or stroke. The study will evaluate the changes in body weight, blood glucose levels, and other metabolic parameters over a 12-week period.
The technical specifications for the study include the use of danuglipron as the investigational medicine, with insulin therapy serving as the control treatment. The study will involve a total of 18 patients, aged 18-99 years, who have type 2 diabetes and a body mass index (BMI) of 25 or higher. The patients will be randomly assigned to either the danuglipron or insulin therapy group and will receive the assigned treatment for 12 weeks.
Alarm and error codes are not applicable in this context as the study is focused on clinical research and not on electronic devices or systems.
User manuals and troubleshooting guides are not relevant to this study as it is a clinical trial and not a product or device that requires user manuals or troubleshooting.
Programming for the study involves the randomization of patients to either the danuglipron or insulin therapy group, and the administration of the assigned treatment for 12 weeks. The study is designed to assess the efficacy and safety of danuglipron in managing blood glucose and weight in patients with type 2 diabetes, and the programming is focused on ensuring that the study is conducted in a controlled and standardized manner.
Installation of the study involves the setup of the clinical trial infrastructure, including the recruitment and screening of patients, the administration of the investigational medicine, and the collection of data on patient outcomes. The installation process is typically managed by the clinical research organization (CRO) or the sponsor of the study, and involves the coordination of multiple stakeholders, including patients, investigators, and research staff.
Go to product